Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Stock Forecast & Price Target
Amneal Pharmaceuticals, Inc. Class A Common Stock · NASDAQ
$17.06-0.38 (-2.18%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Amneal Pharmaceuticals, Inc. Class A Common Stock, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $13.00 to $25.00, a moderate spread. The average target of $18.60 sits 9% above the current $17.06. On the fundamentals, the Street sees revenue growth near 3% this year and 7% next, consensus EPS building from about $0.23 next quarter toward $1.16 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Strong Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Amneal Pharmaceuticals, Inc. Class A Common Stock.
12-MONTH PRICE TARGET
$18.60
+9.0% upside
Average analyst target vs $17.06 current
Highest Target$25.00
Average Target$18.60
Lowest Target$13.00
AMRX EPS & revenue forecast
EPS · NEXT QUARTER
$0.23
Range $0.22 – $0.24 · 5 analysts · +11% YoY
Next period, 5 analysts expect Amneal Pharmaceuticals, Inc. Class A Common Stock to earn $0.23 a share (range $0.22 – $0.24), versus $0.21 a year earlier. Full-year consensus is $1.01, growing to $1.16 the year after.
REVENUE · NEXT QUARTER
$827.0M
Range $803.7M – $843.7M · 5 analysts · +3% YoY
Revenue is expected to reach $827.0M (range $803.7M – $843.7M), +3.0% year-over-year. Full-year consensus is $3.2B, rising to $3.4B next year.
AMRX stock forecast FAQ
Is AMRX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for AMRX?+
The Street-high target is $25.00, and the Street-low is $13.00. The average of all 0 active targets is $18.60.
How many Wall Street analysts cover AMRX?+
5 analysts have an active rating on Amneal Pharmaceuticals, Inc. Class A Common Stock.
What is Amneal Pharmaceuticals, Inc. Class A Common Stock's projected EPS for next quarter?+
The consensus estimate is $0.23 per share (range $0.22 – $0.24) across 5 analysts. Full-year EPS is projected at $1.01, rising to $1.16 the following year.
How much revenue is Amneal Pharmaceuticals, Inc. Class A Common Stock expected to report next quarter?+
Consensus revenue is $827.0M (range $803.7M – $843.7M). Full-year revenue is projected at $3.2B, growing to $3.4B next year.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AMRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
